Leap Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., March 12, 2021 /PRNewswire/ Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the fourth quarter and year ended December 31, 2020.
2020 Leap Highlights:
Signed agreement with BeiGene, Ltd. for rights to Leap s anti-DKK1 antibody, DKN-01, in Asia (excluding Japan), Australia and New Zealand
Completed a $51.75 million public offering of common stock and pre-funded warrants to purchase common stock
Presented updated data from study of DKN-01 plus pembrolizumab in esophagogastric (EGC) cancer demonstrating positive outcomes in DKK1-high patients
Q102 Furry Friday!
iheart.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iheart.com Daily Mail and Mail on Sunday newspapers.
Study finds cancer cells may evade chemotherapy by going dormant
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
FTSE 100 nudges tentatively higher; Rolls Royce well bid after record annual loss (go figure)
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Search jobs 10-Mar-2021 LAVA Therapeutics B.V. to Present Preclinical Findings Supporting Anti-Tumor Activity of Lead Clinical Candidate LAVA-051 at the American Association for Cancer Research (AACR) Virtual 2021 Annual Meeting
UTRECHT, The Netherlands & PHILADELPHIA (BUSINESS WIRE) LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster featuring lead clinical candidate LAVA-051 will be presented at week 1 of the virtual American Association for Cancer Research (AACR) Annual Meeting, which will be held April 10-15, 2021.
The following abstract is now available on the AACR website at www.aacr.org.